References
- WHO | Epilepsy: aISBN public health imperative. ISBN 978-92-4-151593-1. World Health Organization. 2019. Printed in Thailand.
- Ngugi AK, Kariuki SM, Bottomley C, et al. Incidence of epilepsy: A systematic review and meta-analysis. Neurology [Internet]. 2011;77:1005–1012. [cited 2019 Sep 6]. Available from: http://www.neurology.org/cgi/doi/10.1212/WNL.0b013e31822cfc90
- Henning O, Landmark CJ, Henning D, et al. Challenges in epilepsy—The perspective of Norwegian epilepsy patients. Acta Neurol Scand [Internet]. 2019;140:40–47. [cited 2019 Jun 14]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/ane.13098
- Brodie MJ. Diagnosing and predicting refractory epilepsy. Acta Neurol Scand. 2005;112:36–39.
- García-Ramos R, Pastor AG, Masjuan J, et al. Feen report on epilepsy in Spain [Internet]. Neurologia 2011;26:548–555. [cited 2017 Jun 23]. Available from: www.elsevier.es/neurologia
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–319.
- Brodie MJ. Epilepsy: randomised trials and genetic tribulations. Lancet Neurol [Internet]. 2008;7:7–8. cited 2019 Sep 6].
- French JA. Refractory epilepsy: one size does not fit all. Epilepsy Curr [Internet]. 2006;6:177–180. [cited 2019 Sep 6]. Available from: http://journals.sagepub.com/doi/10.1111/j.1535-7511.2006.00137.x
- Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav [Internet]. 2014 [cited 2019 Sep 6];37:59–70.
- Giordano C, Marchiã M, Timofeeva E, et al. Neuroactive Peptides as Putative Mediators of Antiepileptic Ketogenic Diets. Front Neurol. 2014;5 (63): 1-14.
- European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Briviact brivaracetam. Assessment Report EMA/CHMP/822086/2015 Nov.
- Markham A. Brivaracetam: first global approval. Drugs. 2016;76:517–522.
- Willems LM, Bauer S, Rosenow F, et al. Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus. Expert Opin Pharmacother [Internet]. 2019;20:1–11
- Craig D, Rice S, Paton F, et al. Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization: A NICE single technology appraisal. Pharmacoeconomics. 2013 Feb;31(2):101–110.
- Charokopou M, Harvey R, Srivastava K, et al. Relative performance of brivaracetam as adjunctive treatment of focal seizures in adults: a network meta-analysis. Curr Med Res Opin [Internet]. 2019;35:1345–1354
- Chhatwal J. Changing cycle lengths in state-transition models: doing it the right way; [ cited 2018 Jan 23]. Available from: https://www.ispor.org/News/Connections_methodology_state-transition-models.PDF
- Mulhern B, Rowen D, Snape D, et al. Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population. Epilepsy Behav [Internet]. 2014 [cited 2018 Jun 8];36:12–17.
- Kristian B, Wachtmeister K, Stefan F, et al. Retigabine as add-on treatment of refractory epilepsy - a cost-utility study in a Swedish setting. Acta Neurol Scand [Internet]. 2013 [cited 2018 Jan 23];127:419–426.
- Vera-Llonch M, Brandenburg NA, Oster G. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy. Epilepsia. 2008;49:431–437.
- Drummond M, Schulpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford University Press, 2005.
- Barrachina-Martínez I, Vivas-Consuelo D, Piera-Balbastre A. Budget impact analysis of brivaracetam adjunctive therapy for partial-onset epileptic seizures in valencia community, Spain. Clin Drug Investig. 2018 Apr;38(4):353–363.
- Simoens S. Pharmacoeconomics of anti-epileptic drugs as adjunctive therapy for refractory epilepsy. Expert Rev Pharmacoeconomics Outcomes Res [Internet]. 2010;10:309–315. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-77953700981&partnerID=40&md5=902059295990aa17829c1460973dc23c
- Wijnen BFM, van Mastrigt GAPG, Evers SMAA, et al. A systematic review of economic evaluations of treatments for patients with epilepsy. Epilepsia. 2017;58:706–726.
- De Boeck J, Verpoorten K, Luyten K, et al. Comparison between decision trees and markov models to support proactive interfaces. 18th International Workshop on Database and Expert Systems Applications (DEXA 2007); Regensburg; 2007:94–98. [cited 2019 Sep 25]. Available from: https://core.ac.uk/download/pdf/34524516.pdf
- Kotirum S, Muangchana C, Techathawat S, et al. Economic evaluation and budget impact analysis of vaccination against haemophilus influenzae Type b infection in Thailand. Front Public Health [Internet]. 2017;5. [cited 2019 Sep 25]. Available from: http://journal.frontiersin.org/article/10.3389/fpubh.2017.00289/full
- Zhang Y, Wu H, Denton BT, et al. Probabilistic sensitivity analysis on Markov models with uncertain transition probabilities: an application in evaluating treatment decisions for type 2 diabetes. Health Care Manag Sci [Internet]. 2019 [cited 2019 Sep 25];22:34–52.
- Swallow E, Fang A, Signorovitch J, et al. Can matching-adjusted indirect comparison methods mitigate placebo response differences among patient populations in adjunctive trials of brivaracetam and levetiracetam? CNS Drugs [Internet]. 2017;31:899–910.
- Malyshkina NV, Mannering FL. Markov switching multinomial logit model: an application to accident injury severities; 2008 [cited 2019 Sep 25]. Available from: http://arxiv.org/abs/0811.3644
- Hawkins N, Epstein D, Drummond M, et al. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Med Decis Mak [Internet]. 2005 [cited 2019 Sep 25];25:493–510.
- Pinto Prades JL, Sánchez Martínez FI, Abellán Perpiñán JM. Métodos para la evaluación económica de nuevas prestaciones [Internet]. Ministerio de Sanidad y Consumo. 2003. [cited 2019 Sep 25]. Available from: https://dialnet.unirioja.es/servlet/libro?codigo=114939
- Agencia Española del Medicamento. Utilización de medicamentos antiepilépticos en España durante el periodo 2008–2016 [Internet]; 2017 [cited 2019 Sep 25]. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/observatorio/docs/antiepilepticos-periodo-2008-2016.pdf
- Megiddo I, Colson A, Chisholm D, et al. Health and economic benefits of public financing of epilepsy treatment in India: an agent-based simulation model. Epilepsia [Internet]. 2016;57:464–474. [cited 2019 Sep 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26765291
- de Andrés-nogales F, Oyagüez I, Álvarez-Sala LA, et al. Análisis coste-efectividad y coste-utilidad de apixaban frente a dabigatrán y rivaroxaban en el tratamiento y prevención secundaria del tromboembolismo venoso. PharmacoEconomics Spanish Res Artic [Internet]. 2017;14:7–18. [cited 2019 Sep 25]. Available from: http://link.springer.com/10.1007/s40277-016-0064-8
- Romero M, Marrugo R, Paez M. Análisis De Costo Efectividad Y Costo Utilidad De La Adición De Rivaroxabán En El Tratamiento De Pacientes Con Síndrome Coronario Agudo En Colombia. Value Heal [Internet]. 2015;18:A830. [cited 2019 Sep 25]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1098301515023906
- Fricke-Galindo I, Jung-Cook H, LLerena A, et al. Farmacogenética de reacciones adversas a fármacos antiepilépticos. Neurología [Internet]. 2018 [cited 2019 Sep 25];33:165–176.
- Steinhoff BJ, Bacher M, Bucurenciu I, et al. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy—A monocenter survey. Seizure [Internet]. 2017 [cited 2019 Sep 25];48:11–14.
- Chiang H-I, Lim S-N, Hsieh H-Y, et al. Preliminary Asian experience of using perampanel in clinical practice. Biomed J [Internet]. 2018 [cited 2019 Sep 25];33:347.
- Sherina PK. Abdurahiman. current concepts and future perspectives in cost- effectiveness analysis of antiepileptic drugs : a review, Int J Pharm Pharm reseacrh, 2017;10(3):371–379.
- de Kinderen RJA, Wijnen BFM, van Breukelen G, et al. From clinically relevant outcome measures to quality of life in epilepsy: A time trade-off study. Epilepsy Res [Internet]. 2016;125:24–31.
- Cortés J-C, Navarro-Quiles A, Romero J-V, et al. Randomizing the parameters of a Markov chain to model the stroke disease: A technical generalization of established computational methodologies towards improving real applications. J Comput Appl Math [Internet]. 2017 [cited 2018 Jan 10];324:225–240.